Trial Profile
An observational study evaluating preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate for the prevention of sexually acquired HIV infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 08 Sep 2015 New trial record
- 02 Sep 2015 According to a Kaiser Permanente media release, results from this trial were published in the journal, Clinical Infectious Diseases.
- 02 Sep 2015 Results published in a Kaiser Permanente media release.